Key U.S. Gene-Synthesis Screening Deadline Arrives With Replacement Policy Still Unconfirmed

A deadline written into the Biden administration's 2024 Framework for Nucleic Acid Synthesis Screening landed today, October 13, with the policy apparatus it was supposed to govern still unsettled.

The original framework, published by the White House Office of Science and Technology Policy in April 2024 and reviewed by Johns Hopkins Center for Health Security's gene synthesis tracking project, required DNA and RNA synthesis providers to screen orders for sequences of concern. <cite index="21-1">A second stage, planned to take effect October 13, 2026, was intended to impose additional practices including reducing the screening window to 50 nucleotides, screening for sequences known to contribute to toxicity or pathogenicity even when not derived from biological agents, and implementing mechanisms to detect the potential for multiple short sequences to be assembled into longer sequences of concern.</cite>

That second stage never got a clean runway. <cite index="20-4,20-5">Executive Order 14292, signed by President Trump on May 5, 2025, immediately paused new federal funding for dangerous gain-of-function research and rescinded the 2024 DURC/PEPP oversight policy, while giving OSTP sequential deadlines to replace it.</cite> The EO directed OSTP to revise or replace the nucleic acid synthesis framework within 90 days. <cite index="20-3">As of late July 2026, all three OSTP deadlines had passed.</cite>

<cite index="20-7">What could not be independently confirmed as of that writing was whether OSTP had actually published a finalized replacement for the 2024 DURC/PEPP policy, a revised nucleic acid synthesis screening framework, or the non-federally-funded research strategy the order required.</cite> ETL Newswire was unable to confirm publication of a final replacement framework as of today.

The gap matters because the policy tool being debated is a biosecurity chokepoint, not just an administrative process. <cite index="26-3,26-4">Nucleic acid synthesis involves creating new DNA and RNA molecules using chemical processes in the lab, and there are documented concerns that bad actors could have multiple nucleic acid sequences created that, if combined, build the genetic material of a pathogen of concern.</cite> The screening regime is designed to catch those orders before they ship.

<cite index="27-2">The 2024 OSTP framework tried to narrow the short-fragment gap by moving toward 50-nucleotide window screening by October 13, 2026, but that framework is under revision after Executive Order 14292.</cite> That revision's status is the operative unknown.

Legislators have tried to fill the space. <cite index="27-1">In June 2026, an open letter calling for mandatory U.S. nucleic acid synthesis screening and recordkeeping, co-organized by the Foundation for American Innovation and the Institute for Progress, was signed by frontier AI lab representatives.</cite> A separate legislative vehicle, cited in the biosecurityhandbook.com policy tracker, is the Biosecurity Modernization and Innovation Act of 2026, which would <cite index="27-3">direct the Secretary of Commerce to require all gene synthesis providers to screen orders and customers, mandate a federal dangerous-sequence registry, and give OSTP 90 days to identify oversight gaps and develop an implementation plan.</cite> That bill's current status in the Senate could not be confirmed from open sources reviewed for this piece.

The dual-use ambiguity here is real and worth naming plainly: the same short-fragment synthesis capability that a biosecurity screening rule is trying to monitor is also the backbone of legitimate vaccine development, gene therapy research, and diagnostics manufacturing. <cite index="17-3,17-4">The new EO framework requires institutions to implement mechanisms to identify potential dangerous gain-of-function research that is not federally funded, but the policy is still new and its effectiveness remains to be determined.</cite>

The confidence assessment on whether today's deadline has any operational bite is low. There's no public document confirming that a revised OSTP screening framework went final before this date. What's clear at moderate confidence is that the regulatory seam between the old framework's lapse and any successor is real, and the 50-nucleotide threshold that was supposed to close the short-fragment gap is, at best, in legal limbo. The biosecurity community will be watching whether OSTP or Commerce moves first.

Sources cited:
- Johns Hopkins Center for Health Security, Gene Synthesis Screening Policy Tracker (https://genesynthesisscreening.centerforhealthsecurity.org/key-policies)
- CASRAI, Executive Order 14292: Biological Research Security (Jul. 23, 2026) (https://casrai.org/news/executive-order-14292-biological-research-security)
- Frontiers in Bioengineering and Biotechnology, OSTP Framework analysis (2026) (https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2026.1870125/xml)
- Atlantic Council, AI-enabled biological research and accident risk (Oct. 3, 2026) (https://atlanticcouncil.org/dispatches/its-not-just-misuse-ai-enabled-biological-research-also-runs-the-risk-of-accidents)
- Biosecurity Handbook, DNA Synthesis Screening Policy Tracker (https://biosecurityhandbook.com/biotechnology/dna-synthesis-screening.html)
- BGR DC, EO 14292 Administrative Action Summary (May 8, 2025) (https://bgrdc.com/2025-05-08-administrative-action-executive-order-improving-the-safety-of-biological-research/)